Jam

Kulicke & Soffa (K&S) announced the retirement of Chan Pin Chong, EVP & GM of K&S Products & Solutions, effective December 1, 2025. Simultaneously, Ivy Qin and John Molnar, VPs & GMs of Wire Bonding and Advanced Solutions respectively, have been promoted to report directly to CEO Fusen Chen. This organizational restructuring emphasizes agility in the semiconductor market and leverages internal talent to drive growth. The experienced Qin and Molnar will be crucial in navigating technological advancements and global demands in semiconductor manufacturing.

Otter Tail Corporation (Nasdaq: OTTR) will release its Q3 2025 financial results on November 3, 2025, after market close. A conference call and live webcast analyzing the results will be held on November 4, 2025, at 10:00 a.m. CT. Investors and analysts are focused on the company’s performance amid changing energy regulations, commodity prices, and renewable energy demand, as well as its manufacturing segment’s performance. Webcast details and accompanying slides are available at www.ottertail.com/events-and-presentations.

Ynvisible (YNVYF) has been awarded EU funding exceeding €700,000 under the Portugal 2030 program. This investment, co-financed by the EU, will support international marketing, investor engagement, and expansion into key markets, including China and the US, through trade shows like Embedded World North America and CES 2026. The funding will also enhance Ynvisible’s digital presence and product certification efforts. A leadership webinar is scheduled for Oct 15, 2025.

At NBAA-BACE, the NBAA formally endorsed the 2026 Special Olympics Airlift, organized by Textron Aviation. This initiative relies on volunteer pilots and aircraft owners of Cessna, Beechcraft, and Hawker planes to transport athletes to the Special Olympics USA Games in Minneapolis and St. Paul. Since 1987, the Airlift has aided over 10,000 athletes. The 2026 event aims to provide transportation for athletes, highlighting the generosity of the aviation community and requiring meticulous logistical planning and safety measures.

Pennsylvania American Water is offering flexible payment plans to over 300 businesses in Pennsylvania struggling with overdue balances. This initiative aims to support small to medium-sized enterprises facing financial challenges. The company has already enrolled over 100 commercial accounts in installment plans, with more than 300 currently active. The payment arrangements are tailored to each customer’s circumstances. The Pennsylvania Office of Small Business Advocate negotiated with Pennsylvania American Water to establish this program to help small business remain stable.

Albertsons Companies (NYSE: ACI) declared a $0.15 per share cash dividend for Q3 fiscal 2025, payable November 7, 2025, to shareholders of record on October 24, 2025. This announcement arrives amid a complex retail landscape and potential industry consolidation. As of September 6, 2025, Albertsons operates 2,257 stores across 35 states, along with pharmacies, fuel centers, and distribution networks. The company also emphasizes community engagement, contributing significantly to food and financial assistance programs. The press release contains forward-looking statements subject to risks detailed in their Form 10-K.

Empire Metals will engage with investors at the Ignite Investment Summit in Hong Kong and LME Week in London during October 2025. Management will provide updates on the Pitfield Project following the maiden Mineral Resource Estimate. Discussions will focus on the MRE’s implications, project economics, and the path to commercial production of its substantial titanium resources (2.2 billion tonnes grading 5.1% TiO₂). An updated corporate presentation is available on the company website.

Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) is expanding its *ai^² Futures Lab* program through a collaboration with the University of Oregon’s Lundquist College of Business, starting Winter 2026. This initiative connects student teams with biopharmaceutical business development projects, aiming to discover therapeutic assets and nurture future industry leaders. Students will assess early-stage pharmaceutical assets, analyze markets and intellectual property, and identify pathways for patient care. The program, part of Apimeds’ *ai^²* innovation platform, also partners with the University of Alabama and the University of San Diego.

Eisai and BioArctic’s Leqembi Iqlik, a subcutaneous formulation of lecanemab for Alzheimer’s, has been named one of TIME’s ‘Best Inventions of 2025’. This recognition highlights its potential in targeting amyloid-beta. Leqembi, developed through collaboration and based on BioArctic’s research, is approved in multiple countries for early Alzheimer’s. The subcutaneous option offers a more convenient administration route. Analysts predict this award may boost investor confidence in BioArctic and Eisai. BioArctic retains Nordic commercialization rights and receives milestone payments and royalties.

Adlai Nortye Ltd. (NASDAQ: ANL) will present on AN4035, a novel CEACAM5-targeting antibody-drug conjugate (ADC) armed with a pan-RAS(ON) inhibitor, at the AACR-NCI-EORTC conference on October 25, 2025. The presentation will highlight the company’s efforts to develop innovative cancer therapies and address challenging targets like RAS. Further details on AN4035’s scientific rationale and data will be released after the abstract is published on October 22, 2025. AN4035 is designed to potentially broaden the therapeutic window in treating RAS-driven cancers.